Phase II Study on the Efficacy and Safety of the EP1 Receptor Antagonist ONO-8539 for Nonneurogenic Overactive Bladder SyndromeChristopher R. Chapple, Steve Deacon, Michael Small et al.|The Journal of Urology|2013Cited by 35